Dr. Eric Leire, CEO of Genflow Biosciences, joined focusIR’s Katie Pilbeam to discuss how the company is using aging dogs as both a scientific model and a strategic entry into the pet longevity market, aiming to translate those findings into human aging therapies.
He explains how their work targets age-related diseases like MASH, sarcopenia, and glaucoma by focusing on the SIRT6 pathway, which plays a key role in aging across species. Leire emphasizes the importance of extending healthspan, not just lifespan, and balancing investor enthusiasm with the scientific realities and long timelines of aging research.
In this interview, investors will also hear:
- How the company is using dogs as a translational model for aging therapies, which serves both scientific validation and commercial entry into the growing pet longevity market, creating dual revenue and research pathways.
- Why the company is targeting major unmet medical needs such as MASH, sarcopenia, and glaucoma through its SIRT6 gene therapy platform, with a particular focus on treatments that delay or reverse age-related disease, not just manage symptoms.
- What are the primary factors that distinguish the company, with a focus on long-term impact, strategic clinical prioritization, and transparent communication regarding timelines and risks?
Dr. Eric Leire, CEO of Genflow Biosciences was interviewed by Katie Pilbeam for focusIR.
